REX American Resources Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REX research report →
Range $60 – $60
Price Chart
About the company
REX American Resources Corporation, along with its various subsidiaries, manufactures and distributes ethanol across the United States. The company's product portfolio extends to include corn, distillers grains, industrial-grade corn oil, gasoline, and natural gas. Notably, they also supply dry distillers grains with solubles, an important protein component used in animal feed.
- CEO
- Zafar A. Rizvi
- IPO
- 1984
- Employees
- 132
- HQ
- Dayton, OH, US
Get TickerSpark's AI analysis on REX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.43B
- P/E
- 15.41
- Fwd P/E
- 28.86
- PEG
- 0.21
- P/S
- 2.17
- P/B
- 2.28
- EV/EBITDA
- 11.18
- Div Yield
- 0.00%
- Gross Margin
- 16.52%
- Op Margin
- 10.98%
- Net Margin
- 14.13%
- ROE
- 15.77%
- ROIC
- 9.61%
Latest fiscal year · YoY change
- Revenue
- $650.49M+1.2%
- Gross Profit
- $93.71M+2.4%
- Op Income
- $61.09M
- Net Income
- $82.95M+42.6%
- EPS
- $2.50+51.5%
- OCF Growth
- +83.6%
- FCF Growth
- +793.1%
- 52W High
- $53.36
- 52W Low
- $25.60
- 50D MA
- $45.26
- 200D MA
- $39.59
- Beta
- 0.62
- RSI (14)
- 43
- Avg Volume
- 193.92K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Rex American delivered its best first quarter ever on an EPS basis, with higher 45Z tax credits, strong profitability, and continued progress on ethanol expansion and carbon capture projects.· May 28, 2026
- Q1 net income attributable to shareholders rose to $18.5 million, or $0.56 per diluted share, from $8.7 million, or $0.26, a year ago.
- Gross profit increased to $29.1 million from $14.3 million, helped by $7.5 million of 45Z production tax credit income and lower corn costs.
- The company ended the quarter with $364.3 million in cash, cash equivalents and short-term investments and no bank debt.
- Management said the Gibson City ethanol expansion remains on track for completion by the end of 2026.
- The carbon capture project is still moving through EPA class 6 permitting, with Illinois pipeline permitting expected to re-open after the moratorium expires on 07/01/2026.
For Q1 2026, ethanol sales volumes were 71.1 million gallons versus 70.9 million gallons in Q1 2025, and average ethanol selling price was $1.66 per gallon versus $1.76. Gross profit was $29.1 million compared with $14.3 million a year ago; SG&A was $9.7 million versus $5.9 million; income before taxes and noncontrolling interest was $26.1 million versus $13.6 million; and net income attributable to REX shareholders was $18.5 million, or $0.56 per diluted share, versus $8.7 million, or $0.26 per diluted share. The company also recorded $7.5 million in 45Z production tax credit income in the quarter. Looking ahead, management said the Gibson City ethanol expansion remains on schedule for completion by the end of 2026, and they expect a profitable second quarter while continuing to monitor 45Z regulations and regulatory developments around carbon capture.
The CEO framed the quarter as evidence of disciplined execution and long-term value creation, calling it the strongest first quarter in company history on an EPS basis. He emphasized ongoing progress on the ethanol capacity expansion and carbon capture initiative, while noting that both projects are being advanced despite permitting delays and regulatory uncertainty. His tone was confident and constructive, with repeated emphasis on sustainable growth, strong operating conditions, and the ability to adapt to policy changes.
The CFO highlighted the main drivers of improved profitability: higher 45Z income, reduced corn pricing, and solid operating performance. He cited ethanol volume of 71.1 million gallons, gross profit of $29.1 million, SG&A of $9.7 million, and net income of $18.5 million, or $0.56 per diluted share. He also noted $364.3 million in cash, cash equivalents and short-term investments at quarter-end, along with no bank debt, and said the cash decline versus the prior quarter was mainly due to ongoing capital investments in growth projects.
There was no analyst Q&A in the call. Management nonetheless addressed likely investor concerns by updating the status of the EPA class 6 injection well permit, the Illinois carbon pipeline moratorium expiring on 07/01/2026, and ongoing monitoring of Section 45Z policy. They also said they recognized an additional $7.5 million of 45Z production tax credit income in Q1 and are still booking the credit at $0.10 per gallon while regulations are monitored.
The call showed meaningful earnings leverage from 45Z credits and lower corn costs, with record Q1 EPS and a much higher gross profit than last year. Management also described stable domestic demand, strong export markets, and a large cash balance with no debt, which supports continued investment in expansion projects.
The carbon capture project still faces permitting and regulatory delays, including the open EPA class 6 application and the Illinois moratorium through 07/01/2026. The company is also still waiting on clarity around 45Z rules, and management acknowledged that project costs could adjust for inflation and other market factors.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.5%
- Shares Outstanding
- 32.94M
- Float Shares
- 30.80M
of shares held by institutions
234 13F filers
Buy/sell ratio 2.22. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.49M | ▼ 4.66K |
| Vanguard Group Inc | 2.53M | ▲ 93.31K |
| Dimensional Fund Advisors LP | 1.90M | ▼ 68.15K |
| Renaissance Technologies LLC | 1.52M | ▼ 72.04K |
| State Street Corp | 1.45M | ▲ 109.79K |
| Systematic Financial Management LP | 1.11M | ▼ 78.49K |
| Mangrove Partners | 1.02M | 0 |
| Geode Capital Management, LLC | 835.55K | ▲ 139.88K |
| D. E. Shaw & Co., Inc. | 643.89K | ▲ 17.48K |
| American Century Companies Inc | 596.59K | ▼ 107.97K |
| Morgan Stanley | 550.59K | ▼ 26.82K |
| Invesco Ltd. | 528.87K | ▼ 9.90K |
Held by 263 ETFs
Biggest fund positions in REX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | ROSE STUART A | sell | 15,186 |
| Jun 17, 26 | ROSE STUART A | sell | 69,335 |
| Jun 15, 26 | FISHER LEE | other | 2,327 |
| Jun 15, 26 | FISHER LEE | other | 2,096 |
| Jun 15, 26 | Alphonso Mervyn L | other | 2,327 |
| Jun 15, 26 | Alphonso Mervyn L | other | 2,096 |
| Jun 15, 26 | KRESS EDWARD M | other | 2,327 |
| Jun 15, 26 | KRESS EDWARD M | other | 2,096 |
| Jun 15, 26 | ELCAN CHARLES A | other | 2,327 |
| Jun 15, 26 | ELCAN CHARLES A | other | 2,096 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our REX coverage
Recent articles, reports, and earnings notes.
No research on REX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REX report →Amplifying SMH Exposure: REX Shares Debuts SMHU & SMHD
etftrends.com · Aug 4
Investing in the Peptide Boom: REX Files for New Peptide ETF
etftrends.com · Jul 31
T-REX to Launch First-Ever U.S. 2X Inverse DRAM ETF (RAMZ) on July 28
businesswire.com · Jul 23
Betting on the Backbone: REX Files for AI Chipmaking ETF
etftrends.com · Jul 15
T-REX Launches T-REX 2X Long SKHY Daily Target ETF (NYSE Arca: HYNX)
businesswire.com · Jul 14
REX Drone ETF Sees Inflows as Defense Spending Climbs
etftrends.com · Jul 9
What Investors Should Know About This $663,000 REX Insider Sale Amid Record Earnings
fool.com · Jun 24
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses
globenewswire.com · Jun 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.